Search Results

Orphagen Pharmaceuticals, Inc., a biotech company pioneering the screening, discovery, and development of small molecule ligands that modulate orphan or unexplored members of the nuclear receptor family, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for OR-449 for the treatment of pediatric adrenocortical carcinoma (ACC).

Orphagen Pharmaceuticals announced that additional data from its preclinical program to develop OR-449 for the treatment of adrenocortical cancer was presented at the 104th Annual Meeting of the Endocrine Society being held in Atlanta from June 11 to 14.

Orphagen Pharmaceuticals Inc., a biotech company pioneering the screening, discovery, and development of small molecule ligands that modulate orphan or unexplored members of the nuclear receptor family, today announced a late-breaking presentation of new preclinical data for OR-449 at the American Association for Cancer Research (AACR) Annual Meeting 2022 being held April 8-13 both virtually and in-person in New Orleans.

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.